TR201901062T4 - Modifiye meningokokal fhbp polipeptidleri. - Google Patents

Modifiye meningokokal fhbp polipeptidleri. Download PDF

Info

Publication number
TR201901062T4
TR201901062T4 TR2019/01062T TR201901062T TR201901062T4 TR 201901062 T4 TR201901062 T4 TR 201901062T4 TR 2019/01062 T TR2019/01062 T TR 2019/01062T TR 201901062 T TR201901062 T TR 201901062T TR 201901062 T4 TR201901062 T4 TR 201901062T4
Authority
TR
Turkey
Prior art keywords
meningococcal fhbp
fhbp polypeptides
modified meningococcal
modified
polypeptides
Prior art date
Application number
TR2019/01062T
Other languages
English (en)
Inventor
Bottomley Matthew
Masignani Vega
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of TR201901062T4 publication Critical patent/TR201901062T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Buluş sahipleri, meningokokal fHbp varyant 2 ve varyant 3 içinde, bu varyantların özelliklerini geliştirmek maksadıyla modifiye edilebilecek olan artıklar belirleyip tanımlamışlardır.
TR2019/01062T 2014-07-17 2015-07-16 Modifiye meningokokal fhbp polipeptidleri. TR201901062T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14177564 2014-07-17

Publications (1)

Publication Number Publication Date
TR201901062T4 true TR201901062T4 (tr) 2019-02-21

Family

ID=51178812

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01062T TR201901062T4 (tr) 2014-07-17 2015-07-16 Modifiye meningokokal fhbp polipeptidleri.

Country Status (18)

Country Link
US (3) US11066450B2 (tr)
EP (1) EP3169357B1 (tr)
JP (1) JP2017522320A (tr)
KR (1) KR20170023191A (tr)
CN (1) CN106795208A (tr)
AR (1) AR102324A1 (tr)
AU (1) AU2015289192A1 (tr)
BE (1) BE1022641B1 (tr)
BR (1) BR112017000521A2 (tr)
CA (1) CA2954745A1 (tr)
EA (1) EA201692552A1 (tr)
ES (1) ES2722773T3 (tr)
IL (1) IL249822A0 (tr)
MX (1) MX2017000776A (tr)
SG (1) SG11201610945PA (tr)
TR (1) TR201901062T4 (tr)
WO (1) WO2016008960A1 (tr)
ZA (1) ZA201700170B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
KR102626831B1 (ko) 2014-07-17 2024-01-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 수막구균 백신
AU2015289192A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Modified meningococcal fHbp polypeptides
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
JP7165468B2 (ja) * 2016-11-25 2022-11-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ｎＯＭＶ－抗原コンジュゲート及びその使用
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
IT201900003947A1 (it) * 2019-03-19 2020-09-19 Mt Ortho S R L Granulo in materiale metallico biocompatibile per vertebroplastica.
US11976017B2 (en) 2019-12-19 2024-05-07 Dow Technology Investments Llc Processes for preparing isoprene and mono-olefins comprising at least six carbon atoms
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
AU2015289192A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Modified meningococcal fHbp polypeptides
KR102626831B1 (ko) 2014-07-17 2024-01-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 수막구균 백신

Also Published As

Publication number Publication date
EP3169357B1 (en) 2018-11-07
EA201692552A1 (ru) 2017-06-30
AU2015289192A1 (en) 2017-02-02
EP3169357A1 (en) 2017-05-24
IL249822A0 (en) 2017-03-30
ES2722773T3 (es) 2019-08-16
US20220002355A1 (en) 2022-01-06
US20170226161A1 (en) 2017-08-10
MX2017000776A (es) 2017-05-04
BE1022641A1 (fr) 2016-06-23
KR20170023191A (ko) 2017-03-02
CN106795208A (zh) 2017-05-31
JP2017522320A (ja) 2017-08-10
BE1022641B1 (fr) 2016-06-23
WO2016008960A1 (en) 2016-01-21
BR112017000521A2 (pt) 2017-11-21
US20240327470A1 (en) 2024-10-03
US11939357B2 (en) 2024-03-26
AR102324A1 (es) 2017-02-22
US11066450B2 (en) 2021-07-20
CA2954745A1 (en) 2016-01-21
SG11201610945PA (en) 2017-01-27
ZA201700170B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
TR201901062T4 (tr) Modifiye meningokokal fhbp polipeptidleri.
ZA202502076B (en) Chimeric neurotoxins
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
SI3347472T1 (sl) Sestavki, ki obsegajo polipeptide klada CYP76AD1, in uporabe le-teh
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
MX360041B (es) Composiciones y metodos para el cuidado personal.
AU359433S (en) Cleaner
TWD170026S (zh) 容器
AU362107S (en) Compressor inlet for turbocharger
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
TWD174714S (zh) 接合式觸片組之部分
TWD181502S (zh) 閥之部分
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
FI20165686A7 (fi) Tiivistysjärjestely vetouunissa
AU201710543S (en) Portable Light
TWD174083S (zh) 電連接器之部分
AU355238S (en) Dental appliance
EA202090225A3 (ru) Модифицированные менингококковые полипептиды fhbp
AU360397S (en) Extension arm
TWD180703S (zh) 開關上蓋之部分
CA156784S (en) Glass cleaning device
TH1501005684A (th) จุลชีพรีคอมบิแนนท์ที่มีความสามารถในการผลิต 2,3-บิวเทนไดออลที่เพิ่มขึ้น และ วิธีการสำหรับการผลิต 2,3-บิวเทนไดออลโดยการใช้สิ่งเดียวกันนี้